A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the National Cancer Institute-funded Clinical Proteomic Tumor Analysis Consortium (CPTAC) and colleagues around the world, has discovered that the genes we are born with—known as germline genetic variants—play a powerful, underappreciated role in how cancer develops and behaves. Published in the April 14 online issue of Cell [https://doi.org/10.1016/j.cell.2025.03.026], the study is the first to detail how millions of inherited genetic differences influence the activity of thousands of proteins within tumors. Drawing on data from more than 1,000 patients across 10 different cancer types, the research illustrates how a person’s unique genetic makeup can shape the biology of their cancer.

Screening for depression is common in primary care, but providers have few options other than medications to offer those screening positive. The Moodivate app offers a digital version of a behavioral therapy known to reduce depressive symptoms. In a clinical trial conducted at 22 Medical University of South Carolina primary care practices and reported in JAMA Internal Medicine, patients who received the app saw significantly greater reduction in depressive symptoms than those receiving usual care.